Genzyme and Integrated Genetics
Executive Summary
Biotech firms complete merger, announced in April ("The Pink Sheet" April 24, T&G-5), following stockholder approval from both companies on Aug. 14. In a stock swap valued at over $ 31 mil., Integrated Genetics' stockholders receive 0.29 shares of Genzyme for each share of Integrated. In a story on the Xoma and Ingene merger announcement, "The Pink Sheet" (Aug. 14, T&G-1) mistakenly substituted Genetics Institute as Genzyme's merger partner. IG is the partner not GI.